{"url_path":"/sec/apge/8-k/2026-08-11/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1974640/0001140361-26-032231-index.html","accession_number":"0001140361-26-032231","cik":"0001974640","ticker":"APGE","issuer_name":"Apogee Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1974640/0001140361-26-032231-index.html","primary_entity_key":"0001974640","primary_entity_name":"Apogee Therapeutics, Inc."},"word_count":228,"has_tables":true,"body_markdown":"Item 5.02          Departure of Directors or\nCertain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nAs previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 22, 2026, Apogee Therapeutics, Inc.\n(“Apogee”), a Delaware corporation, has entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Andor LLC (“Parent”), a Delaware limited liability company and a wholly owned subsidiary of AbbVie Inc. (“AbbVie”), Andor Merger Co.\n(“Merger Sub”), a Delaware corporation and a wholly owned subsidiary of Parent, and solely for the limited purposes set forth therein, AbbVie, a Delaware corporation, providing for the merger of Merger Sub with and into Apogee (the “Merger”), with\nApogee surviving the Merger as an indirect wholly-owned subsidiary of AbbVie.\n\nIn connection with the anticipated consummation of the Merger, each of the directors of Apogee (Michael Henderson, M.D., Mark C. McKenna, Lisa Bollinger, M.D., Jennifer\nFox, William (BJ) Jones, Jr., Tomas Kiselak and Nimish Shah) has indicated their intention to resign as a member of the board of directors of Apogee and any committee thereof, as applicable, conditioned upon and effective as of the effective time of\nthe Merger. These anticipated resignations are not a result of any disagreement between Apogee and the directors on any matter relating to Apogee’s operations, policies or practices."}